Journal of Comparative Effectiveness Research (Feb 2023)

Non-embolic outcomes in patients with cardiovascular disease and atrial fibrillation treated with rivaroxaban

  • Francisco Marin,
  • Marcelo Sanmartin Fernandez,
  • Gonzalo Baron-Esquivias,
  • Vivencio Barrios,
  • Inaki Lekuona,
  • Alejandro I Perez-Cabeza,
  • Jaime Masjuan,
  • Esther Recalde del Vigo,
  • Jose Manuel Vazquez Rodriguez,
  • Roman Freixa-Pamias,
  • Vanessa Roldan Schilling,
  • Fernando Arribas,
  • Carles Rafols Priu,
  • Manuel Anguita Sanchez

DOI
https://doi.org/10.57264/cer-2022-0049
Journal volume & issue
Vol. 12, no. 3

Abstract

Read online

Aim: It is not well known how comorbidities may change the prognosis of atrial fibrillation (AF) patients. This study was aimed to analyze the impact of cardiovascular disease on this population. Materials & methods: EMIR was a multicenter, prospective study, including 1433 AF patients taking rivaroxaban for ≥6 months. Data were analyzed according to the presence of vascular disease. Results: Coronary artery disease was detected in 16.4%, peripheral artery disease/aortic plaque in 6.7%, vascular disease in 28.3%. Patients with coronary artery disease had higher rates (per 100 patient-years) of major adverse cardiovascular events (2.98 vs 0.71; p < 0.001) and cardiovascular death (1.79 vs 0.41; p = 0.004). Those with vascular disease had higher rates of thromboembolic events (1.47 vs 0.44; p = 0.007), major adverse cardiovascular events (2.03 vs 0.70; p = 0.004), and cardiovascular death (1.24 vs 0.39; p = 0.025). Patients with peripheral artery disease/aortic plaque had similar rates. Conclusion: AF patients with vascular disease have a higher risk of non-embolic outcomes.

Keywords